219 related articles for article (PubMed ID: 29339250)
1. Discovery of novel HSP90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells.
Wei Q; Ning JY; Dai X; Gao YD; Su L; Zhao BX; Miao JY
Eur J Med Chem; 2018 Feb; 145():551-558. PubMed ID: 29339250
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-pyridoyl-Δ
Kadasi S; Yerroju R; Gaddam S; Pullanagiri N; Chary M; Pingili D; Raj S; Raghavendra NM
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900192. PubMed ID: 31808979
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
Jin L; Huang R; Huang X; Zhang B; Ji M; Wang H
Bioorg Med Chem; 2018 May; 26(8):1759-1775. PubMed ID: 29486954
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents.
Amin KM; Eissa AA; Abou-Seri SM; Awadallah FM; Hassan GS
Eur J Med Chem; 2013 Feb; 60():187-98. PubMed ID: 23291120
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.
Li N; Chen C; Zhu H; Shi Z; Sun J; Chen L
Bioorg Chem; 2021 Jun; 111():104867. PubMed ID: 33845380
[TBL] [Abstract][Full Text] [Related]
7. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
[TBL] [Abstract][Full Text] [Related]
8. Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies.
Rana M; Arif R; Khan FI; Maurya V; Singh R; Faizan MI; Yasmeen S; Dar SH; Alam R; Sahu A; Ahmad T; Rahisuddin
Bioorg Chem; 2021 Mar; 108():104665. PubMed ID: 33571809
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities.
Li N; Xu M; Bao N; Shi W; Li Q; Zhang X; Sun J; Chen L
Eur J Med Chem; 2018 Dec; 160():1-8. PubMed ID: 30316059
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
Ma CC; Liu ZP
Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.
Lee JH; Shin SC; Seo SH; Seo YH; Jeong N; Kim CW; Kim EE; Keum G
Bioorg Med Chem Lett; 2017 Jan; 27(2):237-241. PubMed ID: 27914802
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pseudolaric acid A as a new Hsp90 inhibitor uncovers its potential anticancer mechanism.
Liu J; Wu XD; Li W; Yuan Z; Yang K; Zhao QS
Bioorg Chem; 2021 Jul; 112():104963. PubMed ID: 33991836
[TBL] [Abstract][Full Text] [Related]
15. Novel anticancer Hsp90 inhibitor disubstituted pyrazolyl 2-aminopyrimidine compound 7t induces cell cycle arrest and apoptosis via mitochondrial pathway in MCF-7 cells.
Mettu A; Talla V; Naikal SJP
Bioorg Med Chem Lett; 2020 Oct; 30(20):127470. PubMed ID: 32795627
[TBL] [Abstract][Full Text] [Related]
16. Improving the Hsp90 Inhibitors Containing 4-(2,4-Dihydroxyphenyl)-1,2,3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells.
Kazlauskas E; Brukstus A; Petrikas H; Petrikaite V; Cikotiene I; Matulis D
Anticancer Agents Med Chem; 2017 Nov; 17(11):1593-1603. PubMed ID: 28270068
[TBL] [Abstract][Full Text] [Related]
17. 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents.
Zhang Y; Zhang TJ; Li XY; Liang JW; Tu S; Xu HL; Xue WH; Qian XH; Zhang ZH; Zhang X; Meng FH
Eur J Med Chem; 2021 Jan; 210():112988. PubMed ID: 33189438
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
19. Radester, a novel inhibitor of the Hsp90 protein folding machinery.
Shen G; Blagg BS
Org Lett; 2005 May; 7(11):2157-60. PubMed ID: 15901158
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
